
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6354548/publications.pdf Version: 2024-02-01



IANIS M TAURE

#	Article	IF	CITATIONS
1	Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. New England Journal of Medicine, 2012, 366, 2443-2454.	13.9	10,727
2	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 2015, 372, 2509-2520.	13.9	7,696
3	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017, 357, 409-413.	6.0	4,945
4	Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. Journal of Clinical Oncology, 2010, 28, 3167-3175.	0.8	2,667
5	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer, 2016, 16, 275-287.	12.8	2,133
6	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy. Clinical Cancer Research, 2014, 20, 5064-5074.	3.2	2,050
7	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology, 2014, 32, 1020-1030.	0.8	2,015
8	Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Science Translational Medicine, 2012, 4, 127ra37.	5.8	1,837
9	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New England Journal of Medicine, 2016, 375, 1749-1755.	13.9	1,668
10	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 2018, 378, 1976-1986.	13.9	1,495
11	The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. Cancer Discovery, 2015, 5, 43-51.	7.7	1,180
12	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 2542-2552.	13.9	1,048
13	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. New England Journal of Medicine, 2022, 386, 1973-1985.	13.9	871
14	Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma. Cancer Research, 2013, 73, 1733-1741.	0.4	678
15	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer. JAMA Oncology, 2017, 3, 1051.	3.4	658
16	Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer. Cancer Research, 2016, 76, 227-238.	0.4	595
17	Neoadjuvant checkpoint blockade for cancer immunotherapy. Science, 2020, 367, .	6.0	553
18	Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. Clinical Cancer Research, 2013, 19, 462-468.	3.2	485

#	Article	IF	CITATIONS
19	PD-1/PD-L1 inhibitors. Current Opinion in Pharmacology, 2015, 23, 32-38.	1.7	483
20	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. JAMA Oncology, 2019, 5, 1195.	3.4	431
21	Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes. American Journal of Pathology, 2011, 179, 1608-1615.	1.9	423
22	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunology Research, 2017, 5, 417-424.	1.6	400
23	PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 580-588.	3.9	388
24	Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut, 2017, 66, 794-801.	6.1	377
25	Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. Clinical Cancer Research, 2017, 23, 124-136.	3.2	345
26	Alterations of immune response of non-small cell lung cancer with Azacytidine. Oncotarget, 2013, 4, 2067-2079.	0.8	336
27	PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival. Cancer Immunology Research, 2013, 1, 54-63.	1.6	333
28	Detection of Transcriptionally Active High-risk HPV in Patients With Head and Neck Squamous Cell Carcinoma as Visualized by a Novel E6/E7 mRNA In Situ Hybridization Method. American Journal of Surgical Pathology, 2012, 36, 1874-1882.	2.1	308
29	Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Annals of Oncology, 2018, 29, 1853-1860.	0.6	304
30	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Human Pathology, 2016, 47, 52-63.	1.1	284
31	Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology, 2018, 31, 214-234.	2.9	278
32	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. Journal of Clinical Oncology, 2019, 37, 693-702.	0.8	274
33	Antagonists of PD-1 and PD-L1 in Cancer Treatment. Seminars in Oncology, 2015, 42, 587-600.	0.8	259
34	Tumor Regression and Allograft Rejection after Administration of Anti–PD-1. New England Journal of Medicine, 2016, 374, 896-898.	13.9	244
35	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature, 2021, 596, 126-132.	13.7	234
36	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer. Cancer Research, 2019, 79, 1214-1225.	0.4	226

#	Article	IF	CITATIONS
37	Inverse Relationship between Human Papillomavirus-16 Infection and Disruptive <i>p53</i> Gene Mutations in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2008, 14, 366-369.	3.2	213
38	Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. Journal of Clinical Oncology, 2017, 35, 2193-2202.	0.8	209
39	Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. Clinical Cancer Research, 2015, 21, 3969-3976.	3.2	205
40	Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Laboratory Investigation, 2017, 97, 1063-1071.	1.7	156
41	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	5.1	155
42	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. Journal of Clinical Oncology, 2020, 38, 2476-2487.	0.8	152
43	B7-H5 costimulates human T cells via CD28H. Nature Communications, 2013, 4, 2043.	5.8	148
44	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7769-E7777.	3.3	145
45	The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. , 2020, 8, e000155.		140
46	The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncolmmunology, 2016, 5, e1134412.	2.1	135
47	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma. Cancer Immunology Research, 2016, 4, 726-733.	1.6	133
48	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1818-1831.	0.5	133
49	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99.		129
50	Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. Clinical Cancer Research, 2017, 23, 7333-7339.	3.2	128
51	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. Clinical Cancer Research, 2020, 26, 4268-4279.	3.2	126
52	Interleukin-36γ–producing macrophages drive IL-17–mediated fibrosis. Science Immunology, 2019, 4, .	5.6	123
53	Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ TÂCells in Urothelial Carcinoma. Urology, 2015, 85, 703.e1-703.e6.	0.5	122
54	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. Clinical Cancer Research, 2017, 23, 4938-4944.	3.2	120

#	Article	IF	CITATIONS
55	The immune microenvironment of breast ductal carcinoma in situ. Modern Pathology, 2016, 29, 249-258.	2.9	119
56	Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. , 2017, 5, 23.		118
57	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science, 2021, 372, .	6.0	114
58	Keratin-dependent regulation of Aire and gene expression in skin tumor keratinocytes. Nature Genetics, 2015, 47, 933-938.	9.4	111
59	PEG hydrogel degradation and the role of the surrounding tissue environment. Journal of Tissue Engineering and Regenerative Medicine, 2015, 9, 315-318.	1.3	108
60	PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function. Cancer Immunology Research, 2019, 7, 257-268.	1.6	108
61	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. , 2020, 8, e001282.		108
62	Expression of LAGâ€3 and efficacy of combination treatment with anti‣AGâ€3 and antiâ€₽Dâ€1 monoclonal antibodies in glioblastoma. International Journal of Cancer, 2018, 143, 3201-3208.	2.3	101
63	Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) Journal of Clinical Oncology, 2013, 31, 3016-3016.	0.8	101
64	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. Clinical Cancer Research, 2020, 26, 545-551.	3.2	100
65	PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy. Cancer Journal (Sudbury, Mass) Tj ETQ	q110.78	34314 rgBT
66	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 1327-1337.	3.2	90
67	Photoactivated Composite Biomaterial for Soft Tissue Restoration in Rodents and in Humans. Science Translational Medicine, 2011, 3, 93ra67.	5.8	88
68	Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. , 2021, 9, e002568.		87
69	Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. Journal of Translational Medicine, 2015, 13, 214.	1.8	84
70	Merkel Cell Carcinoma: Update and Review. Seminars in Cutaneous Medicine and Surgery, 2011, 30, 48-56.	1.6	82
71	Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy. Clinical Cancer Research, 2017, 23, 3168-3180.	3.2	67
72	Secretory Carcinoma of the Skin Harboring ETV6 Gene Fusions. American Journal of Surgical Pathology, 2017, 41, 62-66.	2.1	66

#	Article	IF	CITATIONS
73	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma. JAMA Oncology, 2017, 3, 974.	3.4	65
74	Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses. Journal of the American Academy of Dermatology, 2012, 67, 717-726.	0.6	63
75	Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. Oncolmmunology, 2014, 3, e963413.	2.1	62
76	Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. Clinical Cancer Research, 2016, 22, 1161-1172.	3.2	57
77	Expression profile and in vitro blockade of programmed deathâ€1 in human papillomavirus–negative head and neck squamous cell carcinoma. Head and Neck, 2015, 37, 1088-1095.	0.9	56
78	PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. Journal of Neuro-Oncology, 2015, 121, 251-259.	1.4	56
79	Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade. American Journal of Surgical Pathology, 2017, 41, 1381-1389.	2.1	54
80	A Novel Role for CD36 in VLDL-Enhanced Platelet Activation. Diabetes, 2003, 52, 1248-1255.	0.3	52
81	Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. Clinical Cancer Research, 2019, 25, 5250-5259.	3.2	46
82	Combined Use of PCR-Based TCRG and TCRB Clonality Tests on Paraffin-Embedded Skin Tissue in the Differential Diagnosis of Mycosis Fungoides and Inflammatory Dermatoses. Journal of Molecular Diagnostics, 2010, 12, 320-327.	1.2	45
83	PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation. Cancer Immunology Research, 2015, 3, 110-115.	1.6	45
84	Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell Reports Medicine, 2020, 1, 100139.	3.3	45
85	PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget, 2018, 9, 19177-19191.	0.8	45
86	A Broad Survey of Cathepsin K Immunoreactivity in Human Neoplasms. American Journal of Clinical Pathology, 2013, 139, 151-159.	0.4	44
87	Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study. , 2021, 9, e002197.		44
88	Benign Nodal Nevi Frequently Harbor the Activating V600E BRAF Mutation. American Journal of Surgical Pathology, 2009, 33, 568-571.	2.1	40
89	PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases. Journal of Cutaneous Pathology, 2010, 37, 938-943.	0.7	37
90	Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ. Journal of Cutaneous Pathology, 2011, 38, no-no.	0.7	37

#	Article	IF	CITATIONS
91	Impact of Elastic Staining on the Staging of Peripheral Lung Cancers. American Journal of Surgical Pathology, 2007, 31, 953-956.	2.1	36
92	Th17 immune microenvironment in Epstein-Barr virus–negative Hodgkin lymphoma: implications for immunotherapy. Blood Advances, 2017, 1, 1324-1334.	2.5	36
93	PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. Modern Pathology, 2017, 30, 1551-1560.	2.9	35
94	Mitochondrial Mutations Are a Late Event in the Progression of Head and Neck Squamous Cell Cancer. Clinical Cancer Research, 2007, 13, 4331-4335.	3.2	34
95	Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. Ca-A Cancer Journal for Clinicians, 2016, 66, 408-436.	157.7	33
96	HHV-8-positive and EBV-positive Intravascular Lymphoma. American Journal of Surgical Pathology, 2014, 38, 426-432.	2.1	32
97	Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors. Frontiers in Oncology, 2018, 8, 649.	1.3	30
98	Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. European Urology Oncology, 2022, 5, 113-117.	2.6	30
99	Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue. Journal of Visualized Experiments, 2013, , .	0.2	28
100	Diagnostic utility of 5â€hydroxymethylcytosine immunohistochemistry in melanocytic proliferations. Journal of Cutaneous Pathology, 2015, 42, 807-814.	0.7	26
101	Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma. Oncolmmunology, 2015, 4, e1029704.	2.1	26
102	Characterization of Human Mesenchymal Stem Cell-Engineered Cartilage: Analysis of Its Ultrastructure, Cell Density and Chondrocyte Phenotype Compared to Native Adult and Fetal Cartilage. Cells Tissues Organs, 2010, 191, 12-20.	1.3	25
103	To Control Site-Specific Skin Gene Expression, Autocrine Mimics Paracrine Canonical Wnt Signaling and Is Activated Ectopically in Skin Disease. American Journal of Pathology, 2016, 186, 1140-1150.	1.9	25
104	The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. Journal of Translational Medicine, 2017, 15, 223.	1.8	25
105	Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. Breast Cancer Research, 2019, 21, 72.	2.2	24
106	Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. Cancer Immunology, Immunotherapy, 2021, 70, 1227-1237.	2.0	23
107	Emerging Immunologic Biomarkers: Setting the (TNM-Immune) Stage. Clinical Cancer Research, 2014, 20, 2023-2025.	3.2	22
108	Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. Cancer Immunology Research, 2019, 7, 805-812.	1.6	22

#	Article	IF	CITATIONS
109	New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy. Patterns, 2021, 2, 100372.	3.1	22
110	Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma. World Neurosurgery, 2020, 135, e187-e193.	0.7	19
111	Increased Expression of <scp>PD</scp> â€1 and <scp>PD‣1</scp> in Patients With Laryngotracheal Stenosis. Laryngoscope, 2021, 131, 967-974.	1.1	18
112	Pleuropulmonary Blastoma: Cytogenetic and Spectral Karyotype Analysis. Pediatric and Developmental Pathology, 2006, 9, 453-461.	0.5	16
113	Primary effusion lymphoma presenting as a cutaneous intravascular lymphoma. Journal of Cutaneous Pathology, 2014, 41, 928-935.	0.7	16
114	PD-L1 expression in inflammatory myofibroblastic tumors. Modern Pathology, 2018, 31, 1155-1163.	2.9	15
115	Langerhans cell density and high-grade vulvar intraepithelial neoplasia in women with human immunodeficiency virus infection. Journal of Cutaneous Pathology, 2007, 34, 565-570.	0.7	14
116	ORAL01.01: A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry. Journal of Thoracic Oncology, 2016, 11, S249.	0.5	11
117	Myofibroma, Myopericytoma, Myoepithelioma, and Myofibroblastoma of Skin and Soft Tissue. Surgical Pathology Clinics, 2011, 4, 745-759.	0.7	10
118	Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas. Melanoma Research, 2017, 27, 85-96.	0.6	10
119	Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer. Prostate, 2022, 82, 706-722.	1.2	10
120	Differentiated (Simplex) Vulvar Intraepithelial Neoplasia: A Case Report and Review of the Literature. American Journal of Dermatopathology, 2011, 33, e27-e30.	0.3	8
121	Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery. Cancer Immunology Research, 2021, 9, 1262-1269.	1.6	8
122	Human papillomavirus prevalence and cytopathology correlation in young Ugandan women using a lowâ€cost liquidâ€based pap preparation. Diagnostic Cytopathology, 2010, 38, 555-563.	0.5	7
123	Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance. , 2021, 9, e002642.		7
124	Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solidÂtumors: Clinical activity, safety, and a potential biomarker for response Journal of Clinical Oncology, 2012, 30, CRA2509-CRA2509.	0.8	7
125	PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors. Cureus, 2019, 11, e6352.	0.2	7
126	Quantitative Assessment of the Immune Microenvironment in Patients With Iatrogenic Laryngotracheal Stenosis. Otolaryngology - Head and Neck Surgery, 2021, 164, 1257-1264.	1.1	6

0.8

1

#	Article	IF	CITATIONS
127	Dermal and Subcutaneous Plexiform Soft Tissue Neoplasms. Surgical Pathology Clinics, 2011, 4, 819-842.	0.7	5
128	Plaque-like syringoma with involvement of deep reticular dermis. Journal of the American Academy of Dermatology, 2014, 71, e206-e207.	0.6	5
129	Perspectives in melanoma: meeting report from the "Melanoma Bridge―(December 5th–7th, 2019,) Tj ET	Qq1_1 0.7	84314 rgBT
130	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop. Clinical Cancer Research, 2021, 27, 394-401.	3.2	5
131	Immune cell subsets in interface cutaneous immuneâ€related adverse events associated with <scp>antiâ€PD</scp> â€I therapy resemble acute graft versus host disease more than lichen planus. Journal of Cutaneous Pathology, 2022, 49, 701-708.	0.7	4
132	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021. Journal of Translational Medicine, 2022, 20, .	1.8	4
133	Poliosis Circumscripta: A Mark of Melanoma. American Journal of Medicine, 2019, 132, 1417-1418.	0.6	3
134	Abstract 6584: The â€~AstroPath' platform for spatially resolved, single cell analysis of the tumor microenvironment (TME) using multispectral immunofluorescence (mIF). , 2020, , .		3
135	Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solidÂtumors: Clinical activity, safety, and a potential biomarker for response Journal of Clinical Oncology, 2012, 30, CRA2509-CRA2509.	0.8	3
136	Data-Rich Spatial Profiling of Cancer Tissue: Astronomy Informs Pathology. Clinical Cancer Research, 2022, 28, 3417-3424.	3.2	3
137	Haemophilus influenzae serotype f purulent pericarditis: a cause of death in a child with Down syndrome. Diagnostic Microbiology and Infectious Disease, 2006, 56, 87-89.	0.8	2
138	Follicular Mucinosis in a Male Adolescent with a History of Acute Myelogenous Leukemia and Graftâ€versusâ€Host Disease. Pediatric Dermatology, 2016, 33, e34-5.	0.5	2
139	PD-L1 and Other Immunological Diagnosis Tools. , 2018, , 371-385.		2
140	Multifocal ischemic necroses of varying age (MINOVA): A distinctive form of atherosclerotic heart disease. Pathology Research and Practice, 2008, 204, 113-120.	1.0	1
141	Different Biomarker Modalities and Response to Anti–PD-1/PD-L1 Therapies—Reply. JAMA Oncology, 2020, 6, 299.	3.4	1
142	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd,) Tj ETQo	0 0 0 rgB	T /Qverlock 1
143	Adaptive immune resistance in gastro-esophageal cancer: Correlating tumoral/stromal PDL1 expression with CD8+ cell count Journal of Clinical Oncology, 2015, 33, 4031-4031.	0.8	1

PDL1 status in muscle-invasive urothelial carcinoma in the context of neoadjuvant cisplatin-based chemotherapy.. Journal of Clinical Oncology, 2015, 33, 300-300.

#	Article	IF	CITATIONS
145	PD-1:PD-L1(B7-H1) pathway in adaptive resistance: A novel mechanism for tumor immune escape in human papillomavirus-related head and neck cancers Journal of Clinical Oncology, 2012, 30, 5506-5506.	0.8	1
146	Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunology Research, 2022, 10, 303-313.	1.6	1
147	Safety and immunologic correlates of allogeneic melanoma GVAX (MelGVAX), a genetically engineered whole-cell melanoma vaccine Journal of Clinical Oncology, 2014, 32, e20001-e20001.	0.8	0